Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21921087 | 0.78 | LRRK2 (0.49) | LRRK2UTS2RNOS1NOS2BRD4 | |
| SCHEMBL25713746 | 0.78 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL15966089 | 0.77 | GRM4 (0.42) | LRRK2UTS2RIRAK4NOS2TYRO3 | |
| SCHEMBL24857977 | 0.76 | JAK2 (0.47) | MEN1KMT2A | |
| SCHEMBL24375255 | 0.76 | LRRK2 (0.39) | LRRK2UTS2RIRAK4NOS1NOS2 | |
| SCHEMBL23001463 | 0.75 | LRRK2 (0.42) | LRRK2UTS2RBRD4ATAD2KDM4E | |
| SCHEMBL30082304 | 0.75 | LRRK2 (0.42) | LRRK2UTS2RMEN1ALDH1A1KMT2A | |
| SCHEMBL18328240 | 0.75 | LRRK2 (0.42) | LRRK2UTS2RIRAK4MEN1ALDH1A1 | |
| SCHEMBL29734745 | 0.75 | LRRK2 (0.42) | LRRK2UTS2RBRD4ATAD2KDM4E | |
| SCHEMBL23811546 | 0.74 | LRRK2 (0.42) | LRRK2UTS2RIRAK4NSD2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | LRRK2 850/4885UTS2R 1873/4885IRAK4 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.